Motif Bio PLC UPDATE ON REVIVE-1 PHASE 3 CLINICAL TRIAL (2555J)
08 Settembre 2016 - 8:01AM
UK Regulatory
TIDMMTFB
RNS Number : 2555J
Motif Bio PLC
08 September 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART
DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO
DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION
This announcement contains inside information.
Motif Bio plc
("Motif Bio" or the "Company")
8 September 2016
UPDATE ON REVIVE-1 PHASE 3 CLINICAL TRIAL
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces an
update to REVIVE-1, one of Motif Bio's two Phase 3 clinical trials
currently enrolling patients with Acute Bacterial Skin and Skin
Structure Infections (ABSSSI).
Patient enrollment for REVIVE-1 has exceeded projections and
data readout is now expected in the second quarter of 2017, rather
than the second half of 2017, as previously stated. REVIVE-2
remains on track with data readout continuing to be expected in the
second half of 2017.
A registration statement relating to these securities has been
filed with the SEC, but has not yet become effective. These
securities may not be sold, nor may offers to buy these securities
be accepted, prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell
or a solicitation of an offer to buy any securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
For further information please contact:
Motif Bio plc info@motifbio.com
Richard Morgan (Chairman)
Graham Lumsden (Chief
Executive Officer)
Zeus Capital Limited
(NOMAD & BROKER)
Phil Walker/Giles Balleny
Dominic Wilson +44 (0)20 3829 5000
Northland Capital Partners
Limited (BROKER)
Patrick Claridge/ David
Hignell
John Howes/ Rob Rees
(Broking) +44 (0)20 3861 6625
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com
PR & IR) Mob: +44 (0)7980 541 893
Paul McManus Mob: +44 (0)7900 608 002
Mike Wort
MC Services AG (EUROPEAN
IR)
Raimund Gabriel +49 (0)89 210 2280
About Motif Bio
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalized patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP), which
is often caused by MRSA (methicillin resistant Staphylococcus
aureus). We are currently enrolling and dosing patients in two
global Phase 3 clinical trials with an intravenous formulation of
iclaprim, for the treatment of ABSSSI, which are expected to be
completed in 2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLFFLVAVIDIIR
(END) Dow Jones Newswires
September 08, 2016 02:01 ET (06:01 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024